AR098232A1 - Métodos de preparación de una formulación oftálmica y usos de la misma - Google Patents
Métodos de preparación de una formulación oftálmica y usos de la mismaInfo
- Publication number
- AR098232A1 AR098232A1 ARP140104061A ARP140104061A AR098232A1 AR 098232 A1 AR098232 A1 AR 098232A1 AR P140104061 A ARP140104061 A AR P140104061A AR P140104061 A ARP140104061 A AR P140104061A AR 098232 A1 AR098232 A1 AR 098232A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently hydrogen
- alkyl
- mixture
- obtaining
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical group O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003885 eye ointment Substances 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002480 mineral oil Substances 0.000 abstract 1
- 235000010446 mineral oil Nutrition 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 229940069265 ophthalmic ointment Drugs 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229910052727 yttrium Inorganic materials 0.000 abstract 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un proceso para preparar una pomada oftálmica, que comprende: (a) la combinación de un compuesto rotor molecular fluorescente con aceite mineral como agente de levigación, obteniendo de este modo una primera mezcla; (b) someter la primera mezcla a agitación con molienda por bolas con un medio de trituración, obteniendo de este modo una segunda mezcla; y (c) la combinación de la segunda mezcla con un vehículo hidrófobo, obteniendo de este modo una pomada. Reivindicación 6: El proceso de la reivindicación 5, en el que el medio de trituración es zirconia estabilizada con itrio. Reivindicación 12: El proceso de una cualquiera de las reivindicaciones anteriores, en el que el compuesto rotor molecular fluorescente tiene la fórmula estructural (1), o una de sus sales farmacéuticamente aceptables, en la que: A¹ es un arileno C₆₋₁₈ opcionalmente sustituido, un heteroarileno C₅₋₁₈ opcionalmente sustituido, o está representado por la fórmula estructural (2); R¹ y R² son cada uno independientemente hidrógeno, alquilo C₁₋₁₂ opcionalmente sustituido, un heteroalquilo C₁₋₁₂ opcionalmente sustituido, cicloalquilo C₃₋₁₂ opcionalmente sustituido, o R¹ y R² tomados junto con el átomo de nitrógeno al que están unidos forman un heterocicloalquilo de 3 a 12 miembros opcionalmente sustituido; R³ y R⁴ son cada uno independientemente hidrógeno, metilo, o etilo; R⁵ es -OH, -O(alquilo C₁₋₆) opcionalmente sustituido, -NR⁶R⁷ o está representado por la fórmula estructural (3); R⁶ y R⁷ son cada uno independientemente, hidrógeno, metilo, etilo o R⁶ y R⁷ tomados junto con el átomo de nitrógeno al que están unidos forman un heterocicloalquilo de 5 a 7 miembros que contiene de uno a tres heteroátomos en el anillo seleccionados independientemente entre N, O, y S; en la que: y es un número entero de 1 a 10; R⁸, cada vez que aparece es independientemente hidrógeno, -OH, o -CH₂OH; R⁹ es hidrógeno, -NR¹⁰R¹¹, -C(O)R¹², alquilo C₁₋₆ opcionalmente sustituido, heteroalquilo C₁₋₆ opcionalmente sustituido; R¹⁰, R¹¹ y R¹² son cada uno independientemente hidrógeno o alquilo C₁₋₆.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898131P | 2013-10-31 | 2013-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098232A1 true AR098232A1 (es) | 2016-05-18 |
Family
ID=51901002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104061A AR098232A1 (es) | 2013-10-31 | 2014-10-29 | Métodos de preparación de una formulación oftálmica y usos de la misma |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150118163A1 (es) |
| EP (1) | EP3062821A1 (es) |
| JP (1) | JP2016539932A (es) |
| AR (1) | AR098232A1 (es) |
| AU (2) | AU2014342327B2 (es) |
| CA (1) | CA2928968A1 (es) |
| NZ (1) | NZ719983A (es) |
| TW (1) | TW201609183A (es) |
| WO (1) | WO2015066270A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013086516A1 (en) | 2011-12-09 | 2013-06-13 | Regents Of The University Of Minnesota | Hyperspectral imaging for early detection of alzheimer's disease |
| AR098232A1 (es) | 2013-10-31 | 2016-05-18 | Cognoptix Inc | Métodos de preparación de una formulación oftálmica y usos de la misma |
| EP3272443A4 (en) * | 2015-03-20 | 2018-12-26 | Hitachi Chemical Company, Ltd. | Method for forming molded article by press molding |
| CN113520301A (zh) | 2016-03-10 | 2021-10-22 | 明尼苏达大学董事会 | 空间-光谱成像方法和视网膜成像设备 |
| EP3621945A4 (en) * | 2017-05-09 | 2021-03-03 | Ambient Photonics, Inc. | STYLE DERIVATIVES FOR THE TREATMENT OF THE CNS AND OTHER DISEASES |
| CN114920567B (zh) * | 2022-04-21 | 2023-05-26 | 苏州瑞瓷新材料科技有限公司 | 一种氧化铝浆料的制备方法及制成的氧化铝浆料 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1281689A (en) | 1968-10-14 | 1972-07-12 | Glaxo Lab Ltd | Steroid 21-phosphates |
| JPH05253508A (ja) * | 1992-03-16 | 1993-10-05 | Sekisui Chem Co Ltd | 膏薬に用いる生薬の微粉砕方法及び膏薬の製造方法 |
| US6417178B1 (en) | 1994-07-19 | 2002-07-09 | University Of Pittsburgh | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits |
| US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| US6659985B2 (en) * | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
| CA2688811A1 (en) * | 2007-05-21 | 2008-11-27 | Neuroptix Corporation | Ophthalmic formulations of amyloid-beta contrast agents and methods of use thereof |
| KR102079160B1 (ko) * | 2009-12-10 | 2020-02-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 아밀로이드 결합제 |
| MX357628B (es) * | 2010-08-16 | 2018-07-17 | Cognoptix Inc Star | Sistema y metodo para detectar proteinas amiloides. |
| AR098232A1 (es) | 2013-10-31 | 2016-05-18 | Cognoptix Inc | Métodos de preparación de una formulación oftálmica y usos de la misma |
-
2014
- 2014-10-29 AR ARP140104061A patent/AR098232A1/es unknown
- 2014-10-29 TW TW103137369A patent/TW201609183A/zh unknown
- 2014-10-30 AU AU2014342327A patent/AU2014342327B2/en not_active Ceased
- 2014-10-30 US US14/528,077 patent/US20150118163A1/en not_active Abandoned
- 2014-10-30 EP EP14799289.5A patent/EP3062821A1/en not_active Withdrawn
- 2014-10-30 JP JP2016527235A patent/JP2016539932A/ja active Pending
- 2014-10-30 NZ NZ719983A patent/NZ719983A/en not_active IP Right Cessation
- 2014-10-30 WO PCT/US2014/063059 patent/WO2015066270A1/en active Application Filing
- 2014-10-30 CA CA2928968A patent/CA2928968A1/en not_active Abandoned
-
2017
- 2017-10-05 AU AU2017245422A patent/AU2017245422B2/en not_active Ceased
-
2018
- 2018-01-08 US US15/864,679 patent/US10350309B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017245422B2 (en) | 2020-04-02 |
| US10350309B2 (en) | 2019-07-16 |
| AU2017245422A1 (en) | 2017-11-02 |
| WO2015066270A1 (en) | 2015-05-07 |
| US20150118163A1 (en) | 2015-04-30 |
| AU2014342327B2 (en) | 2017-07-06 |
| NZ719983A (en) | 2017-11-24 |
| AU2014342327A1 (en) | 2016-06-09 |
| CA2928968A1 (en) | 2015-05-07 |
| TW201609183A (zh) | 2016-03-16 |
| JP2016539932A (ja) | 2016-12-22 |
| US20180126008A1 (en) | 2018-05-10 |
| EP3062821A1 (en) | 2016-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098232A1 (es) | Métodos de preparación de una formulación oftálmica y usos de la misma | |
| AR123048A2 (es) | Moduladores de p2x7 | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CY1122870T1 (el) | Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν | |
| AR103561A1 (es) | Fenilpiridinas herbicidas | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CO2017008600A2 (es) | Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR085602A1 (es) | Inhibidores de quinasas, composiciones farmaceuticas y su aplicacion en el tratamiento de canceres y trastornos autoinmunes | |
| AR098776A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR094550A1 (es) | Inhibidores de btk | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR098432A1 (es) | Compuestos heterocíclicos | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |